09:01 GMT28 November 2020
Listen Live
    Get short URL
    0 150

    MOSCOW (Sputnik) - The EpiVacCorona vaccine against COVID-19, developed by Russian research center Vector, is now in Phase III post-registration clinical trials, the head of the federal public health watchdog, Rospotrebnadzor, said on Tuesday.

    "The peptide antigen-based EpiVacCorona vaccine was [registered] on 13 October and Phase III post-registration trials are currently ongoing", Anna Popova said at an online forum on new scientific data on COVID-19.

    In the middle of October, Russia registered its second coronavirus vaccine, EpiVacCorona, which was developed by the Vector research centre. 

    EpiVacCorona is planned to be introduced into civil circulation on 1 January 2021, according to data from the vaccine registration certificate published in the state registry of medicines. 

    On 11 August, the country registered the world's first COVID-19 vaccine, Sputnik V, it was developed by the Gamaleya Research Institute with support from the Russian Direct Investment Fund (RDIF). 

    Vector, vaccine, COVID-19, Russia
    Community standardsDiscussion